Posted by Michael Wonder on 01 Oct 2021
PharmaMar announces the approval of Zepzelca (lurbinectedin) for the treatment of relapsed stage III or metastatic small cell lung cancer in Canada
30 September 2021 - Lurbinectedin to become commercially available in Canada in the coming months.
PharmaMar has announced today that its licensing partner, Jazz Pharmaceuticals has received conditional approval from Health Canada for Zepzelca (lurbinectedin) for the treatment of adult patients with relapsed stage III or metastatic small cell lung cancer, with disease progression on or after platinum-based chemotherapy.
